Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics
The treatment paradigm for anaplastic glioma has shifted, owing to new diagnostic criteria and new phase III clinical trial evidence. In 2016, the WHO classification of brain tumors including diffuse gliomas was redefined to include molecular criteria, often supplanting the morphological appearance of the tumor cells. This was necessary as prognosis is more closely associated with molecular diagnosis than with morphology and grade. Recently, the benefit of adjuvant chemotherapy in addition to radiotherapy has been demonstrated in both anaplastic oligodendroglioma and anaplastic astrocytoma, as well as lower grade gliomas with the most marked benefit evident in IDH-mutated (astrocytoma) and 1p/19q co-deleted (oligodendroglial) tumors. The defining principle of recent breakthroughs has been the benefit of combinatorial therapy (chemo-radiation) as opposed to treatment in series or treatment of either modality after a period of observation upon evidence of progression.
KeywordsAnaplastic glioma Oligodendroglioma Astrocytoma PCV Temozolomide
Compliance with Ethical Standards
Conflict of Interest
Michael W. Ruff and Joon Uhm declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.•• Loruis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20 This article summarizes the WHO 2016 revision of brain tumor diagnoses.Google Scholar
- 3.• Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508 Characterizes glioma based on molecular profile, with the demonstration that the genetics of glioma (even low grade) are highly predictive of behavior, and in many cases more important than histological grade.CrossRefGoogle Scholar
- 6.•• van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645–53 Demonstrated the benefit of adjuvant TMZ in anaplastic astrocytoma.CrossRefGoogle Scholar
- 12.Co-del-“Radiation Therapy With Concomitant And Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy In Patients With Anaplastic Glioma Or Low Grade Glioma - Full Text View - Clinicaltrials.Gov.” Clinicaltrials.gov. N. p., 2017. Web. 24 Oct. 2017.
- 15.• Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55 Further demonstrates the benefit of adjuvant PCV chemotherapy in low-grade glioma (IDH-mutated with or without 1p/19q codeletion).CrossRefGoogle Scholar
- 16.Mellinghoff, IK et al. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. J Clin Oncol 36, 2018 (suppl; abstr 2002).Google Scholar
- 17.Platten M. A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: a first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). J Clin Oncol 36, 2018 (suppl; abstr 2001).Google Scholar